Eli Lilly's bebtelovimab receives EUA for mild-to-moderate COVID-19

By The Science Advisory Board staff writers

February 15, 2022 -- The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Eli Lilly's antibody bebtelovimab, which demonstrates neutralization against the omicron COVID-19 variant.

Bebtelovimab can now be used for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19. This includes those at risk of hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. The authorized dose of bebtelovimab is 175 mg given as an intravenous injection over at least 30 seconds.

The data supporting this EUA are primarily based on analyses from the phase II BLAZE-4 trial (NCT04634409), treatment arms 9-14. This trial was a phase II, randomized, clinical trial evaluating treatment of nonhospitalized patients with mild-to-moderate COVID-19 who were treated with the authorized dose of bebtelovimab (175 mg) alone or together with 700 mg bamlanivimab and 1,400 mg of etesevimab.

Pseudovirus and authentic virus testing demonstrate that bebtelovimab retains full neutralizing activity against omicron, which is currently the predominant variant in the U.S. In addition, pseudovirus testing with bebtelovimab demonstrates that it retains neutralization against all other known variants of interest and concern, including the BA.2 variant of COVID-19.

Eli Lilly has signed an agreement with the U.S. government to supply up to 600,000 doses of bebtelovimab for at least $720 million.

Combination mAbs shown to be effective COVID-19 treatment
A phase II clinical trial collaboration among Eli Lilly, GlaxoSmithKline, and Vir Biotechnology has shown that a combination of two monoclonal antibodies...
Eli Lilly gets EUA for COVID-19 mAb combo
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to Eli Lilly for the combination of the monoclonal antibodies (mAbs)...
Lilly's mAb highly protective against COVID-19 in nursing homes
Eli Lilly's monoclonal antibody (mAb) LY-CoV555 (bamlanivimab) significantly reduced the risk of contracting COVID-19 among residents and staff of long-term...
Lilly to provide U.S. with 650K more COVID-19 antibody doses
The U.S. government has purchased an additional 650,000 doses of Eli Lilly's neutralizing antibody, bamlanivimab, for $812.5 million.
FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...

Copyright © 2022 scienceboard.net


Conferences
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter